Abstract
The viral safety of biologicals, either human blood derivatives or animal products or recombinant proteins issued from biotechnology, relies on the quality of the starting material, the manufacturing process and, if necessary, the control of the final product. The quality of the starting material is highly guaranteed for blood derivatives due to the individual screening for specific markers (antigens, genome, antibodies) for major blood borne viruses such as hepatitis B and C viruses (HBV, HCV) and human immunodeficiency virus (HIV). It can be reinforced by the detection through amplification procedures (polymerase chain reaction) in the plasma pool of genomes from viruses that have been implicated in contaminations of blood derivatives in the past (parvovirus B19, hepatitis A virus). The association in the manufacturing process of different steps dedicated to purification of plasma proteins (partitioning), virus inactivation (solvent/detergent treatment, heat inactivation) or specific procedures allowing virus removal (nanofiltration) allows to reduce the viral risk very efficiently. The validation studies using scaled down systems and model viruses allow to evaluate the virus safety of any product quantitatively. The aim of t...Continue Reading
References
Apr 1, 1985·Annals of Internal Medicine·C RouziouxD Geroldi
Jul 1, 1995·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·S M Lemon
Dec 1, 1994·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·B HorowitzC Watklevicz
Aug 1, 1995·International Journal of Epidemiology·Z JohnsonI Temperley
May 1, 1997·Transfusion·E SantagostinoM Schiavoni
Feb 12, 1998·Biochemical and Biophysical Research Communications·T NishizawaM Mayumi
Apr 7, 1999·The Journal of Infectious Diseases·M E EysterA Hatzakis
Apr 22, 1999·The New England Journal of Medicine·E Kenny-Walsh
Sep 4, 1999·The New England Journal of Medicine·E Lawlor, G Columb
Dec 22, 1999·Science·J F AndersonH J Van Kruiningen
Mar 24, 2000·Vox Sanguinis·J T AubinB Flan
May 29, 2000·Science·K B ChuaB W Mahy
Sep 1, 2001·Biochimie·D Spillmann
Jan 5, 2002·Journal of Virology·MinKyung Yi, Stanley M Lemon
Oct 19, 2002·Transfusion·Josiane PillonelUNKNOWN Transfusion-Transmissible Agents Working Group of the French Society of Blood Transfusion
Oct 19, 2002·Transfusion·A Omar, C Kempf
Nov 8, 2002·Transfusion·Johannes BlümelAnna Maria Eis-Hübinger
Feb 1, 2003·Haemophilia : the Official Journal of the World Federation of Hemophilia·T Burnouf, M Radosevich
Apr 25, 2003·Lancet·J S M PeirisUNKNOWN SARS study group
Jul 18, 2003·Lancet·Jean-Philippe BrandelAnnick Alpérovitch
Feb 28, 2004·Lancet·J S M PeirisY Guan
Mar 17, 2004·Vox Sanguinis·C MazurierS Chtourou
Apr 14, 2004·Vox Sanguinis·E L DelwartM P Busch
Jun 2, 2004·Journal of Medical Virology·Fatiha NajioullahPatrice André
Aug 20, 2004·The New England Journal of Medicine·Susan L StramerUNKNOWN National Heart, Lung, and Blood Institute Nucleic Acid Test Study Group
May 11, 2007·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·Arnaud Fontanet
Jun 12, 2010·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·P Mouracade